Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice

(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

(2013) Nigel Irwin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice

(2013) Zara J. Franklin et al.   BIOLOGICAL CHEMISTRY

Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice

(2013) N. Irwin et al.   DIABETOLOGIA

desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity

(2013) Nigel Irwin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists

(2013) F.P.M. O’Harte et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

(2013) Sharon A. Sadry et al.   Nature Reviews Endocrinology

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

(2012) N Irwin et al.   INTERNATIONAL JOURNAL OF OBESITY

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

(2012) Sheldon Russell   International Journal of Clinical Pharmacy

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

(2011) J. I. Bagger et al.   DIABETES OBESITY & METABOLISM

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

(2011) F. K. Knop et al.   DIABETES OBESITY & METABOLISM

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

(2011) J. Mu et al.   DIABETOLOGIA

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

(2009) Barry D. Kerr et al.   BIOCHEMICAL PHARMACOLOGY

Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible  -Cell Hyperplasia and Hyperglucagonemia

(2009) W. Gu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS